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AbsTrACT
Objective Management of acute severe Uc (asUc) 
during the novel cOViD-19 pandemic presents significant 
dilemmas. We aimed to provide cOViD-19- specific 
guidance using current British society of gastroenterology 
(Bsg) guidelines as a reference point.
Design We convened a ranD appropriateness panel 
comprising 14 gastroenterologists and an iBD nurse 
consultant supplemented by surgical and cOViD-19 
experts. Panellists rated the appropriateness of 
interventions for asUc in the context of severe acute 
respiratory syndrome coronavirus-2 (sars- coV-2) 
infection. Median scores and disagreement index (Di) were 
calculated. results were discussed at a moderated meeting 
prior to a second survey.
results Panellists recommended that patients with asUc 
should be isolated throughout their hospital stay and 
should have a sars- coV-2 swab performed on admission. 
Patients with a positive swab should be discussed with 
cOViD-19 specialists. as per Bsg guidance, intravenous 
hydrocortisone was considered appropriate as initial 
management; only in patients with cOViD-19 pneumonia 
was its use deemed uncertain. in patients requiring 
rescue therapy, infliximab with continuing steroids was 
recommended. Delaying colectomy because of cOViD-19 
was deemed inappropriate. steroid tapering as per 
Bsg guidance was deemed appropriate for all patients 
apart from those with cOViD-19 pneumonia in whom a 
4–6 week taper was preferred. Post- asUc maintenance 
therapy was dependent on sars-coV-2 status but, 
in general, biologics were more likely to be deemed 
appropriate than azathioprine or tofacitinib. Panellists 
deemed prophylactic anticoagulation postdischarge to be 
appropriate in patients with a positive sars- coV-2 swab.
Conclusion We have suggested cOViD-19- specific 
adaptations to the Bsg asUc guideline using a ranD 
panel.
InTrODuCTIOn
The novel coronavirus severe acute respiratory 
syndrome coronavirus-2 (SARS- CoV-2) was first 
reported in December 2019 and its spread led 
significance of this study
What is already known on this subject?
 ► The British Society of Gastroenterology (BSG) 
has published evidence- based guidelines for 
the management of patients with acute severe 
UC (ASUC), but it is unknown whether these 
are appropriate in the setting of severe acute 
respiratory syndrome coronavirus-2 (SARS- 
CoV-2) infection.
 ► Currently there are limited data to inform 
clinicians in this area and there is no published 
guidance for the management of ASUC in the 
setting of the COVID-19 pandemic.
What are the new findings?
 ► The current BSG IBD guidelines provide a 
management pathway which remains largely 
appropriate during the COVID-19 pandemic.
 ► However, some treatment options were deemed 
uncertain or inappropriate in patients with 
established COVID-19 pneumonia.
 ► It is appropriate to involve COVID-19 specialists 
in decision- making for patients with ASUC who 
are SARS- CoV-2 positive.
 ► Steroid tapering as per BSG guidance was 
deemed appropriate for all patients apart from 
those with COVID-19 pneumonia in whom a 
4–6 week taper was preferred.
 ► Prophylactic anticoagulation postdischarge is 
appropriate in patients with a positive SARS- 
CoV-2 swab.
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significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► This paper summarises available evidence and provides 
expert opinion for the appropriate management of patients 
with ASUC during the COVID-19 pandemic.
 ► It also highlights areas of uncertainty which may help direct 
areas of future research.
to the declaration of a pandemic by the WHO on 11 March 
2020. Infection varies in severity from asymptomatic carriage 
to an acute respiratory illness which, at its most severe, results 
in acute respiratory distress syndrome (ARDS) with hyperin-
flammation and cytokine storm syndrome.1 By mid- May 2020, 
there have been nearly 5 million cases reported worldwide with 
over 300 000 deaths.2 Risk factors associated with more severe 
COVID-19 include older age, male sex, hypertension, cardio-
vascular disease, respiratory disease, diabetes, renal failure and 
ethnicity.3 Neither an effective medical therapy nor a vaccine 
has yet been described, although numerous candidates are under 
evaluation.
Acute severe UC (ASUC) occurs in up to 25% of patients 
with UC and is associated with a mortality of approximately 
1%.4 5 The management of ASUC is particularly challenging in 
the context of SARS- CoV-2 as the typical presenting features 
of ASUC, namely diarrhoea with raised inflammatory markers, 
often in association with a fever, may mimic those of COVID-
19. ASUC is managed with high- dose parenteral corticosteroids, 
progressing to rescue therapy and/or surgery in those who fail 
to respond adequately.6 The safety of all these interventions in 
the context of COVID-19 is unclear. For example, there are 
concerns that corticosteroids may increase the risk of acquiring 
SARS- CoV-2 infection and/or worsen the severity of COVID-
19.7 In addition, the commonly used rescue therapies, infliximab 
and ciclosporin are associated with an increased risk of infection, 
particularly if used in combination with immunomodulators 
such as thiopurines or steroids.8 Finally, individuals in whom 
corticosteroids and rescue therapy fail require urgent colectomy 
which is associated with high morbidity and mortality in patients 
infected with SARS- CoV-2.9 However, withholding treatment in 
ASUC is clearly not an option in view of the high mortality (in 
excess of 20%) associated with such an approach.10
While national and international registries continue to collate 
data regarding patients with IBD with COVID-19, very few 
cases relate to the management of ASUC. The PREPARE IBD 
(physician response to disease flares and patient adaptation in 
response to events in IBD during theCOVID-19 pandemic) study 
( www. prepareibd. org) is collecting data from patients with IBD 
who are admitted to hospital during the pandemic, as well as 
from those who develop confirmed or suspected SARS- CoV-2 
infection. As of 8 May 2020, 19 patients with severe active UC 
including four with suspected or confirmed COVID-19 had 
been identified (S Sebastian, personal communication, 2020). 
The Surveillance Epidemiology of Coronavirus Under Research 
Exclusion- IBD registry (https:// covidibd. org/) is collating data 
on patients with IBD with confirmed coronavirus, with 1074 
patients included to date, the majority of whom have Crohn’s 
disease; details of how many in the cohort have ASUC are not 
yet available.11 Finally, in case series from Italy and Spain, 4 of 79 
and 1 of 40 patients, respectively, had COVID-19 in conjunction 
with ASUC12 13 (the number of patients with ASUC in the Italian 
case series was provided on request from authors).
Treatment of ASUC during the COVID-19 pandemic pres-
ents substantial management dilemmas in the absence of a high- 
quality evidence base to guide clinicians. We therefore aimed to 
address this deficit of informed guidance by convening a RAND 
appropriateness panel. Current British Society of Gastroenter-
ology (BSG) guidelines were used as a reference point to high-
light differences to current management.6
MeTHODs
study overview
The RAND/UCLA (University of California, Los Angeles) appro-
priateness method uses a modified Delphi panel approach and 
combines expert opinion with the best available evidence to 
determine the appropriateness of specific practices in certain 
clinical situations.14 It is particularly useful in areas of uncer-
tainty in which evidence is insufficient to guide day- to- day clin-
ical practice, such as in the COVID-19 pandemic.15
The aim of this RAND panel was to provide clarity on the 
management of ASUC, as defined by Truelove and Witts criteria, 
in the context of the COVID-19 pandemic.10 The panel sought 
to identify areas where it was appropriate to deviate from current 
BSG ASUC guidance and consider alternative strategies.
We assembled a 15- person panel comprising representatives 
from the BSG IBD Section Committee, the BSG IBD Clinical 
Research Group (CRG) and other gastroenterologists, each 
from different IBD centres across the UK, as well as an IBD 
nurse consultant (online supplementary table 1). A web- based 
questionnaire was created and iteratively improved before 
being completed by all panellists prior to a moderated online 
meeting. We circulated a list of relevant publications with the 
questionnaire, comprising the current BSG guidelines on the 
management of ASUC6 along with up- to- date publications about 
COVID-19 in general and specifically in relation to IBD. Due 
to the rapid growth of available data, the panel used a range of 
instant messaging services to disseminate publications that were 
not available at the time of the initial literature review.
Panellists rated the appropriateness of management options 
at five different time points during the course of admission for 
ASUC (admission, first- line therapy, rescue therapy, continued 
medical therapy and surgery) in the context of absence of, or 
varying severity of SARS- CoV-2 infection. They were asked to 
grade the appropriateness of specific interventions on a scale 
of 1–9 (where 1–3 is inappropriate, 4–6 is uncertain and 7–9 
is appropriate). The responses were summarised and anony-
mised before being presented at a virtual meeting in May 2020 
with the aim of allowing discussion which ensured a common 
understanding of the questions and which focused on areas of 
disagreement, without trying to force consensus. Also present 
at the meeting were non- voting specialists who provided expert 
opinion with regards to IBD surgery (PT, LH), rheumatology 
(JG), intensive care (MG), respiratory medicine (FC) and infec-
tious diseases (AU). In practice, several specialities may provide 
expert opinion in COVID-19 management, including intensiv-
ists, respiratory physicians and infectious disease physicians. We, 
therefore, used the encompassing term ‘COVID-19 specialist’ to 
represent this group. Finally, the Chairs of the BSG IBD Section 
Committee (IA) and the BSG IBD CRG (CAL) were also present. 
The moderators (PMI, MAS) neither expressed opinions on 
management nor voted, but were experts both in RAND panels 
and in the management of IBD. After the meeting, a second 
online survey comprising 91 questions, which had been slightly 
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Figure 1 5- Adaptations to the BSG guideline for the management of ASUC in the context of COVID-19. ASA, 5- aminosalicylic acid; ASUC, acute 
severe UC; BSG, British Society of Gastroenterology; C.difficle, Clostridium difficile; CMV, cytomegalovirus; CRP, C reactive protein; ECCO, European 
Crohn's and Colitis Organisation; ESPGHAN, European Soceity for Paediatric Gastroenterology, Hepatology and Nutrition; IV, intravenous; LMW, low 
molecular weight; SARS- CoV-2, severe acute respiratory syndrome coronavirus-2; TNF, tumour necrosis factor.
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Table 1 Appropriateness of patient isolation and investigation in 
patients admitted with acute severe UC in the context of the COVID-19 
pandemic
On admission Prior to rescue therapy Prior to colectomy
Inpatient 
isolation
All patients
SARS- CoV-2 
swab
Performed in all 
patients
Repeat swab if initial 
swab negative
Repeat swab if initial 
swab negative
Flexible 
sigmoidoscopy
≤24- hour 
admission
If not performed If not performed
If already performed If already performed
CT chest Performed in all 
patients
Performed in all 
patients
CT abdomen 
and pelvis
Performed in all 
patients
Green is considered appropriate, yellow uncertain and red inappropriate.
SARS- CoV-2, severe acute respiratory syndrome coronavirus-2.
modified from the initial questionnaire following discussion at 
the meeting, was circulated for completion.
Several assumptions were made for clarity. First, patients were 
assumed to have a confirmed diagnosis of UC with intercurrent 
gastrointestinal infection having been excluded. Second, if this 
was not an index presentation, patients were assumed to have 
received optimised 5- aminosalicylic acid therapy prior to admis-
sion and were also presumed to be biological- naive. In addition, 
where ciclosporin was suggested as an option, it was assumed 
that the patient was thiopurine- naive. Third, other than those 
areas addressed in the survey, the management of ASUC was 
assumed to be in line with BSG guidance.6 Finally, where steroid 
weaning or discontinuation was considered, it was assumed that 
patients could safely stop steroids without the risk of Addisonian 
crisis.
In addition, in the section about first- line medical therapy, 
panellists assumed patients were not steroid refractory. For the 
rescue therapy section, patients were assumed to have ongoing 
ASUC despite 3 days of intravenous corticosteroid therapy 
and had reached standard criteria for rescue therapy.16 For the 
continuing medical therapy section, patients were assumed to 
have responded to intravenous corticosteroids sufficiently to 
switch to oral prednisolone and were ready to be discharged 
from hospital. Lastly, as per RAND methodology, respondents 
were advised to make decisions without considering local avail-
ability of treatments or cost.
Analysis
For each scenario, median scores were calculated with a score of 
<3.5 being considered inappropriate, ≥3.5 but <6.5 uncertain 
and ≥6.5 appropriate. We used the validated RAND disagree-
ment index (DI) to define disagreement among panellists using 
the equation outlined below.14 A DI ≥1 denotes disagreement. 
Any scenario in which disagreement was found was scored as 
uncertain, regardless of the median score.
 
DI = 70%ile−30%ile
2.35+
(
1.5×abs
(
5− 70%ile+30%ile2
))
 
resulTs
Overall results
Of the 91 clinical scenarios, panellists rated 28 as appropriate, 
19 as uncertain and 44 as inappropriate. After the second round 
of voting, agreement was present for all scenarios (DI<1). The 
key findings are summarised below and their relationship to 
current BSG guidance is highlighted in figure 1. A detailed list 
of all scenarios, complete with median score, appropriateness 
rating and DI can be found in online supplementary table 2.
Indications for investigations, inpatient isolation and 
specialist referral
The panellists agreed that all patients admitted to hospital with 
ASUC should have a SARS- CoV-2 swab performed on admis-
sion. If the result was negative it was deemed appropriate to 
repeat the swab at the point of requiring rescue therapy and/or 
surgery to exclude subclinical infection. It was also considered 
appropriate to isolate all patients throughout their hospital stay, 
irrespective of their COVID-19 status (table 1).
It was rated appropriate to perform a flexible sigmoidoscopy 
within 24 hours of admission. If a patient had not had a flexible 
sigmoidoscopy on admission, it was considered appropriate that 
one should be performed prior to rescue therapy or colectomy. 
Repeating this test at these time points was deemed unneces-
sary in patients who had already had a flexible sigmoidoscopy 
performed.
Routine CT scanning of the abdomen/pelvis on admission 
(in addition to abdominal X- ray) was deemed inappropriate. 
However, the appropriateness of routine chest CT on admission 
was rated as uncertain. The one scenario in which a CT scan 
of the chest was felt to be appropriate for all patients irrespec-
tive of COVID-19 status was in the context of patients requiring 
colectomy.
Throughout the scenarios, the panellists considered the 
appropriateness of discussion with COVID-19 specialists. In 
patients without symptoms or signs of COVID-19 and with a 
negative swab, this was deemed inappropriate if receiving first- 
line therapy but uncertain in patients requiring rescue therapy. 
However, it was considered appropriate in all patients with a 
positive swab, irrespective of the presence of symptoms or signs 
of COVID-19.
Initial treatment of AsuC
As per BSG guidance, intravenous hydrocortisone, 100 mg, four 
times per day (or equivalent) was rated appropriate as the initial 
management of patients presenting with ASUC in the absence 
of symptoms and signs of COVID-19 pneumonia. In patients 
with COVID-19 pneumonia, use of hydrocortisone was deemed 
uncertain. Other possible treatments (poorly bioavailable oral 
steroids, for example, budesonide multimatrix and beclometa-
sone modified release, infliximab either with or without steroids, 
ciclosporin or tofacitinib) were considered inappropriate. The 
exception was infliximab (without steroids) which was consid-
ered uncertain in patients with a positive swab for SARS- CoV-2, 
either with or without signs of COVID-19 pneumonia. Ambula-
tory outpatient management with daily intravenous methylpred-
nisolone was rated as inappropriate in all patients with ASUC 
regardless of SARS- CoV-2 status, as was management by imme-
diate colectomy unless complications mandating emergency 
surgery were present such as toxic megacolon, perforation or 
severe haemorrhage (table 2).
rescue therapy
In patients meeting criteria for escalation of management at day 
3, it was considered inappropriate to avoid rescue therapy by 
continuing monotherapy with intravenous corticosteroids, irre-
spective of COVID-19 status. Instead, the panellists deemed that 
following standard BSG guidance by initiating infliximab and 
continuing steroids was appropriate, whereas treatment with 
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Table 2 Appropriateness of treatment options in acute severe UC in the context of the COVID-19 pandemic: first- line medical therapy
First- line medical therapy
Negative COVID-19 swab WITHOUT 
respiratory symptoms
Inpatient intravenous 
steroids*
Poorly bioavailable steroids† IFX alone Tofacitinib Discussion with COVID-19 specialist‡
Ambulatory intravenous 
steroids§
Intravenous steroids*+IFX Ciclosporin Colectomy   
Positive COVID-19 swab WITHOUT 
respiratory symptoms or signs of 
COVID-19 pneumonia
Inpatient intravenous 
steroids*
Poorly bioavailable steroids† IFX alone Tofacitinib Discussion with COVID-19 specialist‡
Ambulatory intravenous 
steroids§
Intravenous steroids*+IFX Ciclosporin Colectomy   
Positive COVID-19 swab WITH symptoms 
or signs of COVID-19 pneumonia
Inpatient intravenous 
steroids*
Poorly bioavailable steroids† IFX alone Tofacitinib Discussion with COVID-19 specialist‡
Ambulatory intravenous 
steroids§
intravenous steroids*+IFX Ciclosporin Colectomy   
Green is considered appropriate, yellow uncertain and red inappropriate.
*Steroids, intravenous hydrocortisone 100 mg four times a day or intravenous methylprednisolone 60 mg daily as an inpatient.
†Budesonide MMX 9 mg/beclometasone 5 mg once daily orally as an inpatient; IFX (either 5 mg/kg or 10 mg/kg).
‡Discussion with appropriate COVID-19 specialist as per local availability.
§Intravenous methylprednisolone 60 mg daily as an outpatient.
IFX, infliximab; MMX, multimatrix.
Table 3 Appropriateness of treatment options in acute severe UC in the context of the COVID-19 pandemic: rescue therapy
rescue therapy
Failure of rescue 
therapy
Negative COVID-19 swab WITHOUT 
respiratory symptoms
Continue intravenous 
steroids alone
IFX +steroids Intravenous ciclosporin 
+steroids
Colectomy Delay surgery
  IFX, stop steroids Intravenous ciclosporin, stop 
steroids
Discussion with COVID-19 
specialist*
Positive COVID-19 swab WITHOUT 
respiratory symptoms or signs of 
COVID-19 pneumonia
Continue intravenous 
steroids alone
IFX +steroids Intravenous ciclosporin 
+steroids
Colectomy Delay surgery
  IFX, stop steroids Intravenous ciclosporin, stop 
steroids
Discussion with COVID-19 
specialist*
Positive COVID-19 swab WITH 
symptoms or signs of COVID-19 
pneumonia
Continue intravenous 
steroids alone
IFX +steroids Intravenous ciclosporin 
+steroids
Colectomy Delay surgery
  IFX, stop steroids Intravenous ciclosporin, stop 
steroids
Discussion with COVID-19 
specialist*
Green is considered appropriate, yellow uncertain and red inappropriate. Steroids, intravenous hydrocortisone 100 mg four times daily or intravenous methylprednisolone 60 mg 
daily as an inpatient; IFX (either 5 mg/kg or 10 mg/kg).
*Discussion with appropriate COVID-19 specialist as per local availability.
IFX, infliximab.
infliximab in conjunction with immediate steroid withdrawal 
was deemed uncertain. The BSG guidelines also recommend 
ciclosporin as an alternative rescue therapy. However, the RAND 
panel voted that ciclosporin, either with or without ongoing 
steroids, was inappropriate in all scenarios other than in patients 
with a negative SARS- CoV-2 swab in whom it was rated uncer-
tain. Finally, colectomy without rescue therapy was deemed 
inappropriate in all the scenarios considered by the panel. 
However, once colectomy became necessary, for example where 
rescue therapy had failed or when complications had occurred, it 
was deemed inappropriate to delay surgery, even in patients with 
COVID-19 pneumonia (table 3).
Continuing medical therapy
The ongoing management of patients who had responded to 
intravenous corticosteroids and were ready for discharge on 
oral steroids was also considered. In patients with a negative 
SARS- CoV-2 swab, or with a positive swab but without signs 
or symptoms of pneumonia, steroid tapering over 6–8 weeks 
as per BSG guidance was deemed appropriate. However, in 
patients with COVID-19 pneumonia it was rated uncertain. 
Accelerated steroid withdrawal over 4–6 weeks was rated 
appropriate regardless of COVID-19 status. More rapid with-
drawal over 4 weeks was deemed inappropriate except in 
patients with COVID-19 pneumonia, in whom it was rated 
uncertain. The use of poorly bioavailable oral steroids as an 
alternative to a standard steroid taper was rated as inappro-
priate in all scenarios (table 4).
Initiation of additional therapy prior to or soon after discharge 
to prevent relapse was also considered. Following BSG guidance 
by initiating a thiopurine was rated uncertain in SARS- CoV-2 
swab- negative patients and inappropriate in swab- positive 
patients. Use of biological therapy (anti- tumour necrosis factor 
(TNF), ustekinumab or vedolizumab) was deemed appropriate 
in swab- negative patients. In all other patients, the appropriate-
ness of biological therapy was uncertain, except for anti- TNF 
therapy in patients with a positive swab but without pneumonia 
in whom treatment was rated as appropriate. Tofacitinib was 
generally rated as inappropriate except in swab- negative patients 
in whom it was rated uncertain.
Finally, panellists were asked whether patients should be 
discharged with a period of ongoing prophylactic anticoag-
ulation. This was deemed appropriate in patients who had a 
positive SARS- CoV-2 swab regardless of whether they had 
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Table 4 Appropriateness of treatment options in acute severe UC in the context of the COVID-19 pandemic: continuing medical therapy
Continuing medical therapy*
Negative COVID-19 swab WITHOUT 
respiratory symptoms
Standard steroid taper Accelerated steroid taper 
<4 weeks
Thiopurine† Ustekinumab† Tofacitinib†
Accelerated steroid taper 
4–6 weeks
Poorly bioavailable 
steroids‡
Anti- TNF† Vedolizumab† Thromboprophylaxis§
Positive COVID-19 swab WITHOUT 
respiratory symptoms or signs of COVID-19 
pneumonia
Standard steroid taper Accelerated steroid taper 
<4 weeks
Thiopurine† Ustekinumab† Tofacitinib†
Accelerated steroid taper 
4–6 weeks
Poorly bioavailable 
steroids‡
Anti- TNF† Vedolizumab† Thromboprophylaxis§
Positive COVID-19 swab WITH symptoms or 
signs of COVID-19 pneumonia
Standard steroid taper Accelerated steroid taper 
<4 weeks
Thiopurine† Ustekinumab† Tofacitinib†
Accelerated steroid taper 
4–6 weeks
Poorly bioavailable 
steroids‡
Anti- TNF† Vedolizumab† Thromboprophylaxis§
Green is considered appropriate, yellow uncertain and red inappropriate.
*Patient has responded to intravenous steroid therapy.
†Steroid taper and start additional therapy at or soon after discharge.
‡Switch from corticosteroids to budesonide MMX 9 mg daily/beclometasone 5 mg daily.
§Continue for a period after discharge.
MMX, multimatrix; TNF, tumour necrosis factor.
pneumonia but was rated uncertain in those who had negative 
swabs.
DIsCussIOn
General considerations
The recent International Organisation For the Study of Inflam-
matory Bowel Disease RAND appropriateness panel addressing 
the use of medications to treat IBD in the COVID-19 era did not 
specifically address the management of patients with ASUC.7 To 
date, there has been no consensus on how to manage this condi-
tion during the COVID-19 pandemic; in the context of a limited, 
although rapidly evolving evidence base, this is perhaps unsur-
prising.17 Thus, there is an urgent need for guidance on how 
best to manage ASUC in the current setting. Several areas need 
consideration in this regard including: the effect of SARS- CoV-2 
on the activity and course of IBD; the effect of IBD and its 
activity on the risk of being infected with SARS- CoV-2 and 
the progression to COVID-19; the interaction of SARS- CoV-2/
COVID-19 with the drugs used to treat IBD; and the possible 
effects of treatments for COVID-19 on IBD.
SARS- CoV-2 is found in the gut and RNA is measurable in the 
stool significantly longer than in serum or respiratory samples18 
although the significance of this is unclear. The effects of the 
virus on the intestinal mucosa remain undefined, as does its 
interaction with inflamed tissue.19 Gastrointestinal symptoms 
including diarrhoea occur in around 30% of patients and have 
been associated with worse outcome,20 21 and a single report 
describes a possible case of COVID-19 colitis.22
Currently, it is not clear whether IBD- specific factors lead 
to worse outcomes in patients who develop COVID-19. In the 
Italian series of 79 patients with IBD and COVID-19, active 
disease was associated with the risk of COVID-19 pneumonia 
even after controlling for other risk factors.12 Furthermore, active 
IBD was also significantly associated with increased hospitalisa-
tion, the need for respiratory support and death. In contrast, 
in Bergamo, Northern Italy, an observational study reported no 
cases of COVID-19 in 522 patients with IBD.23 While there are 
data that suggest that active IBD increases the risk of some viral 
infections,24 it is difficult to draw firm conclusions with regard 
to SARS- CoV-2 infection given the limited data available.
Of concern to most clinicians caring for patients with IBD 
is the possible risk of the drugs used to manage ASUC in the 
context of the COVID-19 pandemic. Intravenous corticoste-
roids remain the most widely used induction therapy in ASUC,25 
but it is uncertain how they may influence outcome in patients 
with SARS- CoV-2 infection and COVID-19. Corticosteroids 
are known to increase the risk of sepsis and respiratory tract 
infections and may also increase viral replication and suscepti-
bility to SARS- CoV-2.26 27 There is also evidence that steroids 
may increase morbidity and/or mortality from some respiratory 
viruses such as influenza, Middle East respiratory syndrome and 
SARS- CoV,26 28–30 although steroids have an established role in 
the management of ARDS.31 Beyond corticosteroids, immuno-
modulators such as thiopurines, biologics and tofacitinib are 
frequently used at various stages of the management of ASUC and 
there is also a lack of data regarding their safety in the context 
of the SARS- CoV-2 pandemic. Finally, it is important to consider 
the possible effects of drugs used to manage COVID-19 on IBD. 
For example, interleukin 6 inhibitors are being tested in patients 
with COVID-19 ( ClinicalTrials. gov Identifier: NCT04315298) 
but have been associated with intestinal perforation in IBD.
We used an established methodology, a RAND appropriate-
ness panel, to produce guidance in this challenging clinical area. 
Regarding initial management, there was agreement that all 
patients with ASUC should be managed as inpatients. Ambula-
tory care was considered inappropriate, since patients with ASUC 
need regular monitoring and involvement of a multidisciplinary 
team, this type of complex care being difficult to deliver in the 
outpatient setting. While there was some support for ambula-
tory management to avoid patients being admitted, thereby 
decreasing the risk of nosocomial acquisition of SARS- CoV-2, 
the risks of managing ASUC as an outpatient were considered 
to outweigh this possible benefit. Furthermore, in scenarios in 
which patients had confirmed SARS- CoV-2 infection, no such 
benefit existed. Nevertheless, in view of the acknowledged risk 
of contracting SARS- CoV-2 infection in hospital, it is perhaps 
unsurprising that the panel considered it appropriate to isolate 
patients with ASUC in a side room wherever possible.
The panel deemed it uncertain whether a CT chest should 
be performed in all patients on admission. While a CT chest 
is more sensitive than a chest X- ray (CXR) in detecting signs 
of early or limited infection, the COVID-19 specialists advised 
that a CXR would suffice in asymptomatic patients on admis-
sion. However, the Royal College of Radiologists has advised 
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a low- dose CT chest should be performed in patients who are 
having a CT abdomen as part of the investigation of an abdom-
inal emergency.32–34
It was considered appropriate to involve a COVID-19 specialist 
in all scenarios in the presence of a positive SARS- CoV-2 swab, 
regardless of signs or symptoms of COVID-19 pneumonia. The 
panel was uncertain whether this was required in patients with a 
negative SARS- CoV-2 swab who required rescue therapy. During 
the meeting, concern was expressed by some panellists about 
the possible effects of corticosteroids and rescue therapies on 
SARS- CoV-2 infection and COVID-19 pneumonia driving the 
need to seek clarification from COVID-19 experts and high-
lighting the need for further research.
First-line therapy
It was considered appropriate to follow the BSG guidelines 
on the initial management of ASUC in patients without signs 
or symptoms of COVID-19, regardless of SARS- CoV-2 swab 
results. Only in patients with COVID-19 pneumonia was there 
uncertainty among the panel regarding the appropriateness of 
conventional therapy with intravenous corticosteroids, largely 
driven by concerns of possible harm. However, it should be 
noted that in this challenging condition in which there is scant 
experience and almost no published data in relation to COVID-
19, of all suggested treatments, intravenous corticosteroids 
were given the highest median score by the panel. Regarding 
the ongoing uncertainty about the benefits or harms of cortico-
steroids in patients with COVID-19 pneumonia and the incon-
clusive data emerging from the current coronavirus pandemic, 
the results of the adaptive trial, RECOVERY, which includes a 
dexamethasone arm, are eagerly awaited.1 Nevertheless, leaving 
ASUC untreated is associated with a high risk of death, mortality 
being at least 24% in the days before the use of corticosteroids.25 
The expert advisers supported the WHO position that steroid 
use should not be avoided because of theoretical risks in patients 
with COVID-19.35
The panel was uncertain whether infliximab, without concur-
rent corticosteroids, should be used as a first- line therapy in 
patients who are SARS- CoV-2 positive, regardless of whether 
they had COVID-19. As with corticosteroids, the risk of anti- TNF 
in the context of the pandemic is unknown. In addition, there is 
no high- quality evidence for infliximab in ASUC other than as a 
rescue therapy following corticosteroid failure. Anti- TNF agents 
are known to increase the risk of respiratory tract and other 
opportunistic infections,36 particularly when used in associa-
tion with thiopurines and corticosteroids.37 However, anti- TNF 
therapies are currently being evaluated in clinical trials38 as a 
potential treatment for COVID-19- induced cytokine storm.39 40 
In view of the uncertainty of the effects of corticosteroids and 
infliximab on SARS- CoV-2 infection, it was considered appro-
priate that all patients with a positive swab should be discussed 
with a COVID-19 specialist to guide decision- making.
rescue therapy
Up to half of patients with ASUC fail first- line medical therapy 
with corticosteroids.6 In all scenarios, it was considered inap-
propriate to continue this treatment alone in the face of non- 
response at day 3, consistent with current BSG guidelines.6 
Similarly, in line with BSG guidance, it was considered appro-
priate to commence infliximab while continuing corticosteroids 
regardless of SARS- CoV-2 status. Discontinuation of cortico-
steroids at the point of commencing infliximab rescue therapy 
was considered of uncertain appropriateness across all scenarios, 
as it may result in worsening colitis, while acknowledging the 
potential risks of combining the two drugs. Ciclosporin rescue 
therapy was generally considered inappropriate, due in part to 
concerns about the risks of drug- induced nephrotoxicity given 
the frequency of acute kidney injury in SARS- CoV-2 infection.41 
In addition, the infusion regimen requires frequent healthcare 
worker–patient contact which could, in theory, increase the risk 
of transmission. The panel did not explore its use in settings 
in which infliximab may be relatively contraindicated, such as 
previous loss of response to infliximab, drug immunogenicity 
or when relevant comorbidities exist, such as multiple sclerosis. 
Similarly, the panel did not specifically address the question of 
whether infliximab was used as a monotherapy or in combina-
tion with an immunomodulator.
There is little evidence regarding the risks of surgical manage-
ment in patients with COVID-19. Preliminary data demonstrate 
a substantial increase in morbidity and mortality among patients 
infected with SARS- CoV-2 undergoing surgery. In one report, 
34 patients underwent elective surgery in Wuhan, China, with 
all developing COVID-19 pneumonia, 7 of whom (20%) died.9 
Accordingly, the risks of surgery drove the rating of colectomy as 
first- line therapy or as an alternative to rescue therapy, as being 
inappropriate. However, in patients failing medical therapy, there 
was consensus that delaying surgery would be inappropriate.
Continuing medical therapy
The BSG IBD guidelines recommend corticosteroid tapering 
over 6–8 weeks which was considered appropriate by the 
panel, except in the context of COVID-19 pneumonia where 
an accelerated taper over 4–6 weeks was considered appro-
priate instead. A more accelerated taper, over fewer than 4 
weeks, was generally deemed inappropriate due to the high risk 
of relapse in this cohort.6 Regarding initiation of maintenance 
therapy either before or shortly after discharge from hospital, 
it was considered appropriate to start anti- TNF, vedolizumab 
or ustekinumab in patients with negative swabs. However, in 
scenarios in which patients had positive swabs, with or without 
evidence of COVID-19 pneumonia, there was uncertainty about 
the risk:benefit ratio of biological therapy, driven by the lack 
of evidence. Thus, biological use in this situation was deemed 
uncertain in nearly all scenarios.
Thiopurines and tofacitinib were not considered appropriate 
at any stage during the scenarios. This is despite the BSG recom-
mendation that thiopurines should be initiated at or soon after 
discharge following successful treatment of ASUC.6 Azathioprine 
therapy was in part considered inappropriate due to possible side 
effects such as pancreatitis, which could result in readmission to 
hospital, and drug hypersensitivity, which can manifest as a flu- 
like syndrome which may potentially be confused with COVID-
19.42 Azathioprine can also induce significant lymphopaenia42 
which may mimic the lymphopaenia seen in SARS- CoV-2 infec-
tion. How this affects outcome of COVID-19 is unclear; some 
reports even suggest a theoretical benefit of thiopurines.43 44 
The additional monitoring required when azathioprine is initi-
ated may also be a challenge with COVID-19- related service 
reconfiguration and antecedent risks of SARS- CoV-2 acquisition 
posed by the requirement for face- to- face contact from labora-
tory monitoring.
Tofacitinib is a non- selective Janus kinase inhibitor which is 
associated with herpes zoster viral reactivation and, like COVID-
19, is also associated with an increased risk of deep vein throm-
bosis.45 There is also very limited evidence for its use in the 
setting of ASUC.46 For these reasons, the panel considered its 
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use inappropriate in nearly all settings although it was noted that 
its rapid offset of action could be of theoretical benefit.
Anticoagulation
Prophylactic anticoagulation was considered appropriate 
beyond discharge among patients with a positive SARS- CoV-2 
swab, although this strategy was deemed uncertain in people 
with negative swabs. Like ASUC, COVID-19 is strongly linked 
to a hypercoagulable state with substantially increased risk of 
microthrombi and venous thromboembolism (VTE).47 It is 
notable that the British Thoracic Society recommends doubling 
the dose of anticoagulation and/or prescribing VTE prophylaxis 
(low- molecular- weight heparin or direct oral anticoagulant) for 
up to 4 weeks following discharge in high- risk patients with 
COVID-19.48
strengths and limitations
The strengths of our study include the inclusion of a diverse 
group of IBD experts drawn from a wide range of UK centres 
as well as non- gastroenterology specialists with experience in 
managing patients with COVID-19. In addition, we used the 
RAND methodology which is a validated technique to guide 
decision- making in the absence of a robust evidence base. It 
is not necessarily an attempt to reach consensus but rather to 
guide clinicians as to the appropriateness or inappropriateness 
of interventions, while accepting that uncertainty is also a valid 
outcome, which was highly appropriate in this setting. It was 
impossible for our scenarios to encompass fully all cases encoun-
tered in clinical practice. We, therefore, focused on principles 
that may help to guide decision- making in most cases of ASUC 
in the context of COVID-19. We appreciate that by doing so, 
this guidance may not be directly applicable to more nuanced 
cases where decision- making may be influenced by a myriad of 
factors. Nor was every aspect of care considered; for example, 
the question of repeating testing for Clostridium difficile prior 
to colectomy in view of higher exposure to antibiotics in the 
COVID-19 era was not addressed. The outcomes should, there-
fore, be considered an adjunct to multidisciplinary decision- 
making rather than a replacement. Finally, knowledge within the 
field remains fast moving such that it will be important to stay 
abreast of new developments as they arise.
Implications and concluding remarks
By combining clinical expertise from the BSG CRG and IBD 
Section Committee in conjunction with other medical and 
surgical IBD and COVID-19 experts, we have provided guidance 
to clinicians regarding the appropriate management of ASUC 
during the COVID-19 pandemic, highlighting where current 
BSG guidance may need adaptation. Population- based studies 
are needed to clarify the risks and benefits of interventions used 
in the management of ASUC during the pandemic. Until then, we 
consider the results of the panel, which largely support following 
the well- established and evidence- based BSG guideline, will help 
guide clinicians in this challenging and evolving area.
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